Where Biogen Stands With Analysts
Where Biogen Stands With Analysts
Biogen在分析師中的立場
20 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives.
20位分析師分享了他們最近三個月對Biogen（納斯達克股票代碼：BIIB）的評估，表達了看漲和看跌的觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的評級，展示了過去30天情緒的演變，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $294.95, a high estimate of $364.00, and a low estimate of $215.00. This current average represents a 4.71% decrease from the previous average price target of $309.54.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲294.95美元，最高估計爲364.00美元，低估值爲215.00美元。目前的平均價格比之前的平均目標股價309.54美元下降了4.71％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
An in-depth analysis of recent analyst actions...
對分析師近期行爲...
登入免費觀看全文
登入/註冊